151 related articles for article (PubMed ID: 28746220)
21. Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?
Güth U; Huang DJ; Schötzau A; Wight E
Arch Gynecol Obstet; 2010 Feb; 281(2):339-44. PubMed ID: 19554341
[TBL] [Abstract][Full Text] [Related]
22. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
23. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Mayer AR; Homesley HD
J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
[TBL] [Abstract][Full Text] [Related]
24. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Cooke SL; Ng CK; Melnyk N; Garcia MJ; Hardcastle T; Temple J; Langdon S; Huntsman D; Brenton JD
Oncogene; 2010 Sep; 29(35):4905-13. PubMed ID: 20581869
[TBL] [Abstract][Full Text] [Related]
25. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
26. The clinical benefit of array-based comparative genomic hybridization for detection of copy number variants in Czech children with intellectual disability and developmental delay.
Wayhelova M; Smetana J; Vallova V; Hladilkova E; Filkova H; Hanakova M; Vilemova M; Nikolova P; Gromesova B; Gaillyova R; Kuglik P
BMC Med Genomics; 2019 Jul; 12(1):111. PubMed ID: 31337399
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
28. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Petrillo M; Pedone Anchora L; Tortorella L; Fanfani F; Gallotta V; Pacciani M; Scambia G; Fagotti A
Gynecol Oncol; 2014 Aug; 134(2):257-61. PubMed ID: 24910451
[TBL] [Abstract][Full Text] [Related]
29. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
30. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
Liu BL; Liu SJ; Baskys A; Cheng H; Han Y; Xie C; Song H; Li J; Xin XY
BMC Cancer; 2014 Nov; 14():829. PubMed ID: 25399490
[TBL] [Abstract][Full Text] [Related]
31. Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study.
Amira G; Morsi A; Fayek IS; Mansour O; Nader H
Asian Pac J Cancer Prev; 2019 Feb; 20(2):621-627. PubMed ID: 30806069
[TBL] [Abstract][Full Text] [Related]
32. Therapy for recurrent ovarian cancer.
Kuhn WC
Curr Womens Health Rep; 2003 Feb; 3(1):33-8. PubMed ID: 12521548
[TBL] [Abstract][Full Text] [Related]
33. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
[TBL] [Abstract][Full Text] [Related]
34. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
35. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
[TBL] [Abstract][Full Text] [Related]
36. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
37. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
38. The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep; 2006 Nov; 8(6):448-54. PubMed ID: 17040623
[TBL] [Abstract][Full Text] [Related]
39. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
40. Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Pujade-Lauraine E; Banerjee S; Pignata S
J Clin Oncol; 2019 Sep; 37(27):2437-2448. PubMed ID: 31403868
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
